Data as of Aug 21
| -0.04 / -2.25%|
Echo Therapeutics, Inc. is a transdermal medical device company with significant expertise in advanced skin permeation technology. The company is involved in developing Prelude SkinPrep System, which is a platform technology to allow painless skin permeation that would enable both needle-free drug delivery and analyte extraction; and Symphony CGM System, a non-invasive, wireless, and transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. It also engages in the development of specialty pharmaceuticals based on its proprietary AzoneTS transdermal drug reformulation technology. The company's drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. Echo Therapeutics was founded on September 14, 2007 and is headquartered in Philadelphia, PA.
|Kimberly A. Burke||CEO, Secretary, Chief Compliance Officer & SVP|
|Marshall D. Deweese||Senior Vice President-Operations|
|Charles Thomas Bernhardt||Chief Financial Officer|
|Kenneth Gary||Senior Vice President-Research & Development|
|Mary McNamara-Cullinane||Vice President-Regulatory & Clinical Affairs|